Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with poor prognosis and access to anti-HER2 treatment is still a challenge in lower-middle income countries. The availability of the biosimilar trastuzumab has improved access by lowering the costs. We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Joel, Anjana, Georgy, Josh Thomas, Thumaty, Divya Bala, John, Ajoy Oommen, Chacko, Raju Titus, Rebekah, Grace, Sigamani, Elanthenral, Chandramohan, Jagan, Manipadam, Marie Therese, Cherian, Anish Jacob, Abraham, Deepak Thomas, Jacob, Paul Mazhuvanchary, Sebastian, Patricia, Backianathan, Selvamani, Singh, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057782/
https://www.ncbi.nlm.nih.gov/pubmed/33912232
http://dx.doi.org/10.3332/ecancer.2021.1207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057782/
https://www.ncbi.nlm.nih.gov/pubmed/33912232
http://dx.doi.org/10.3332/ecancer.2021.1207

Ejemplares similares